Evidence map›Paper›PMID 33311442›Full record

ArticleCell death & disease2020

CircRNA hsa_circRNA_104348 promotes hepatocellular carcinoma progression through modulating miR-187-3p/RTKN2 axis and activating Wnt/β-catenin pathway.

Guanqun Huang, Min Liang, Haiyan Liu, Jianhong Huang, Peiqing Li, Chong Wang, Yidan Zhang, Ye Lin, Xianhan Jiang

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 208 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
208citing papers in PubMed, 1 pooled it
16.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

208 citing papers in PubMed, 1 synthesis or guideline pooled it, 343 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

148 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Guanqun HuangDepartment of General Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, 510700, Guangzhou City, Guangdong Province, China. huangguanqun666@163.com.
Min LiangDepartment of General Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, 510700, Guangzhou City, Guangdong Province, China.
Haiyan LiuPhase I Clinical Trial Center, The Fifth Affiliated Hospital of Guangzhou Medical University, 510700, Guangzhou City, Guangdong Province, China.
Jianhong HuangDepartment of General Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, 510700, Guangzhou City, Guangdong Province, China.
Peiqing LiDepartment of General Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, 510700, Guangzhou City, Guangdong Province, China.
Chong WangDepartment of General Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, 510700, Guangzhou City, Guangdong Province, China.
Yidan ZhangDepartment of General Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, 510700, Guangzhou City, Guangdong Province, China.
Ye LinDepartment of General Surgery, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 510080, Guangzhou City, Guangdong Province, China. 25410818@qq.com.
Xianhan JiangDepartment of Abdominal Oncology, The Fifth Affiliated Hospital of Guangzhou Medical University, 510700, Guangzhou City, Guangdong Province, China. jiangxianhangz@126.com.
Guangzhou Medical University · CNGuangdong Academy of Medical Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circular RNAs (circRNAs) have confirmed to participate in diverse biological functions in cancer. However, the expression patterns of circRNAs on hepatocellular carcinoma (HCC) remains unclear. In the present study, we clarified that hsa_circRNA_104348 was dramatically upregulated in HCC tissues and cells. Patients with HCC displaying high hsa_circRNA_104348 level possessed poor prognosis. Has_circ_104348 facilitated proliferation, migration, and invasion, meanwhile suppressed apoptosis of HCC cell. Furthermore, hsa_circRNA_104348 directly targeted miR-187-3p, could regulate miR-187-3p to affect proliferation, migration, invasion, and apoptosis of HCC cells, and may have effect on Wnt/β-catenin signaling pathway. Moreover, RTKN2 could be a direct target of miR-187-3p. In addition, knockdown of hsa_circRNA_104348 attenuated HCC tumorigenesis and lung metastasis in vivo. Taken together, these findings indicated that circular RNA hsa_circRNA_104348 might function as a competing endogenous RNA (ceRNA) to promotes HCC progression by targeting miR-187-3p/RTKN2 axis and activating Wnt/β-catenin pathway.

Indexed as

Disease ProgressionWnt Signaling PathwayAnimalsApoptosisBase SequenceCarcinoma, HepatocellularCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHEK293 CellsHumansIntracellular Signaling Peptides and ProteinsLiver NeoplasmsMaleIntracellular Signaling Peptides and ProteinsMicroRNAsMIRN187 microRNA, humanRNA, CircularRTKN2 protein, human

Identifiers

PMID33311442
PMCPMC7734058
OpenAlexW3112029431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.